Browse all 651 ETFs by category, no search needed
Global 185
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
SPDR S&P Biotech (XBI)
Look-through valuation · Sector · Expense ratio 0.35 % · ISIN US78464A8707
Price history (since 2006)
Monthly close since 2006. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Twist Bioscience Corp TWST | 1.9 % | n/a | n/a |
| Moderna Inc MRNA | 1.8 % | n/a | n/a |
| Natera Inc NTRA | 1.6 % | −94.3 % | 37 |
| Crispr Therapeutics AG CRSP | 1.6 % | −70.1 % | 30 |
| Spyre Therapeutics Inc. SYRE | 1.5 % | n/a | n/a |
| AbbVie Inc ABBV | 1.5 % | −2.0 % | 73 |
| TG Therapeutics Inc TGTX | 1.5 % | −74.8 % | 53 |
| Biogen Inc BIIB | 1.5 % | +10.0 % | 63 |
| Halozyme Therapeutics Inc HALO | 1.5 % | +12.6 % | 79 |
| Gilead Sciences Inc GILD | 1.5 % | +31.1 % | 83 |
| Oruka Therapeutics, Inc. ORKA | 1.5 % | n/a | n/a |
| Amgen Inc AMGN | 1.5 % | +10.0 % | 63 |
| Biomarin Pharmaceutical Inc BMRN | 1.4 % | +10.0 % | 67 |
| Protagonist Therapeutics Inc PTGX | 1.4 % | −91.7 % | 39 |
| Incyte Corporation INCY | 1.4 % | +64.6 % | 91 |
| Regeneron Pharmaceuticals Inc REGN | 1.4 % | +56.1 % | 72 |
| Exelixis Inc EXEL | 1.4 % | +89.6 % | 94 |
| Vertex Pharmaceuticals Inc VRTX | 1.4 % | +10.0 % | 79 |
| Alkermes Plc ALKS | 1.4 % | +13.0 % | 65 |
| United Therapeutics Corporation UTHR | 1.4 % | +62.2 % | 72 |
| PTC Therapeutics Inc PTCT | 1.4 % | +155.0 % | 61 |
| Krystal Biotech Inc KRYS | 1.4 % | +12.9 % | 71 |
| Madrigal Pharmaceuticals Inc MDGL | 1.4 % | n/a | n/a |
| Travere Therapeutics Inc TVTX | 1.4 % | −87.2 % | 35 |
| Alnylam Pharmaceuticals Inc ALNY | 1.4 % | −11.4 % | 66 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 50 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +87.2 % below FV
- 2 FXI iShares China Large-Cap ETF +57.2 % below FV
- 3 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +43.7 % below FV
- 4 MCHI iShares MSCI China ETF +41.9 % below FV
- 5 ITB iShares U.S. Home Construction ETF +31.4 % below FV
- 6 TAN Invesco Solar ETF +26.0 % below FV
- 7 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +19.4 % below FV
- 8 FDNI First Trust Dow Jones International Internet ETF +19.3 % below FV
- 9 ESPO VanEck Video Gaming and eSports ETF +18.3 % below FV
- 10 XIDV Franklin International Dividend Booster Index ETF +17.9 % below FV
Frequently asked about XBI
Is XBI overvalued?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of XBI?
What is the expense ratio of XBI?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives SPDR® S&P Biotech ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Sep 25, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.